#France #ACROBiosystems #Villejuif #The HIVE #Campus Grand Parc

ACROBiosystems Establishes Local Presence in France

ACROBiosystems, a prominent global biotechnology firm, is enhancing its footprint in France by inaugurating a specialized hub at the The HIVE Innovation Center, located at the Grand Parc Campus in Villejuif. This strategic move is part of a broader initiative to integrate with key players in life sciences and contribute to the vibrant local ecosystem.

A Leading Force in Biopharmaceuticals

Founded in 2010, ACROBiosystems has rapidly emerged as a pivotal partner in the global biopharmaceutical sector. With nearly 1,000 employees worldwide, the company operates in various regions, including Europe, North America, and Asia. Its clientele comprises thousands of organizations, from leading pharmaceutical and biotechnology firms to research institutions.

The company’s extensive portfolio supports all phases of drug development, from recombinant proteins to antibodies, assay kits, and custom scientific services in compliance with Good Manufacturing Practices. ACROBiosystems has firmly positioned itself in areas such as oncology, cell and gene therapies, immunotherapy, and their clinical applications. Its rigorous quality control measures ensure that the products used in biopharmaceutical research, development, and clinical applications meet stringent standards.

Emphasis on Local Engagement

ACROBiosystems has chosen The HIVE Innovation Center as its base of operations to better connect with the local community. This center is home to numerous biotechnology companies, hospitals, translation research institutes, and clinical partners, creating an ideal environment for fostering collaboration. Since joining the Paris Saclay Cancer Cluster in 2025, ACROBiosystems has begun building relationships within the regional life sciences community, and this new office will further strengthen those ties.

The establishment of a centralized hub allows ACROBiosystems to engage in daily interactions that drive innovation and collaboration, which is vital for the company's mission of partnering with clients from the discovery phase through to clinical trials. By embedding itself in this dynamic scientific community, ACROBiosystems can provide exceptional quality and attentive service to its partners.

Commitment to Scientific Excellence

Mike Chen, founder and CEO of ACROBiosystems, emphasizes the importance of being located at the heart of a global scientific research hub like Paris-Saclay. He states, “We are not merely establishing a satellite office; our aim is to be an integral part of this ecosystem, actively listening, collaborating, and evolving alongside teams working on the next generation of cancer treatments, innovative therapies, and beyond.”

Sandrine Lo, Head of Investments and Asset Management at Kadans Science Partner, echoes this sentiment, highlighting ACROBiosystems' choice of the Grand Parc Campus as a strong indicator of the growing appeal of this innovative ecosystem on a global scale.

About ACROBiosystems

ACROBiosystems Group, listed since 2021, is dedicated to becoming an essential pillar of the global biopharmaceutical and healthcare industries. With subsidiaries like bioSeedin, Condense Capital, and ACRODiagnostics, the company adds value to the pharmaceutical sector by continually advancing new technologies and products. ACROBiosystems positions itself at the forefront of accelerating drug development, including targeted therapies and immunotherapeutics, thereby making significant contributions to global health.

About Kadans Science Partner

Kadans Science Partner leads the European market in investing in and developing ecosystems and properties tailored to knowledge-intensive sectors. The company is committed to uniting innovators capable of tackling global challenges through specialized assets. With a network spanning over 30 scientific hubs, Kadans is actively working to expand its influence and support scientific enclaves across Europe.

In conclusion, ACROBiosystems' strategic opening at The HIVE signifies not only its commitment to creating meaningful collaborations but also reflects the burgeoning success of France's biotechnological landscape and its dedication to advancing healthcare innovation.